Clinical Stage Biotech

Beam Therapeutics – 2026-01-12 - Increase Confidence 8/10

Negative free cash flow offset by $1.25B cash runway and FDA breakthroughs; BEAM-302 & risto-cel catalysts drive near-term upside.